Search Within

Yvette J Bernal

Formats
  1. Meeting Abstract (22)
  2. Journal Article (9)
  3. Research Letter (1)
Groups
  1. Adult Leukemia (32)
  2. Center for Hematologic Malignancies (32)
  3. Department of Medicine (32)
  4. Hematologic Malignancies, Division of (32)
  5. GSK Faculty (31)
  6. Hematologic Malignancies Research (31)

More Groups

People
  1. Jae Park (30)
  2. Renier Brentjens (29)
  3. Isabelle Riviere (28)
  4. Xiuyan Wang (27)
  5. Michel Sadelain (26)
  6. Elizabeth Halton (19)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2019 (5)
  4. 2018 (4)
  5. 2017 (4)
  6. 2016 (1)

More Years

Publications
  1. Blood (13)
  2. Journal of Clinical Oncology (6)
  3. Molecular Therapy (3)
  4. Blood Advances (2)
  5. Hematological Oncology (2)
  6. Science Translational Medicine (2)

More Publications

Publishers
  1. American Society of Hematology (15)
  2. American Society of Clinical Oncology (6)
  3. Nature Publishing Group (4)
  4. American Association for the Advancement of Science (2)
  5. Wiley Blackwell (2)
  6. Amer Soc Clinical Investigation Inc (1)

More Publishers

Results (32)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia
    Journal Article

    Maslak, P. G.; Dao, T.; Bernal, Y.; Chanel, S. M.; Zhang, R.; Frattini, M.; Rosenblat, T.; Jurcic, J. G.; Brentjens, R. J.; Arcila, M. E.; more...
    Blood Advances (2018)

    Fulltext@MSK | Save
  • A phase I trial of CD19-targeted EGFRt/19-28z/4-1BBL armored chimeric antigen receptor (CAR) modified T cells in patients with relapsed or refractory chronic lymphocytic leukemia
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X.; Senechal, B.; Bernal, Y.; Halton, E.; Diamonte, C.; Wang, Y.; Brentjens, R. J.; Sadelain, M.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Durable long-term survival of adult patients with relapsed B-ALL after CD19 CAR (19-28z) T-cell therapy
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X.; Senechal, B.; Wang, Y.; Mead, E.; Santomasso, B.; Halton, E.; Diamonte, C.; Bernal, Y.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Development and evaluation of a human single chain variable fragment (scFv) derived BCMA targeted CAR T Cell vector leads to a high objective response rate in patients with advanced MM
    Meeting Abstract

    Smith, E. L.; Mailankody, S.; Ghosh, A.; Masakayan, R.; Staehr, M.; Purdon, T. J.; Halton, E.; Diamonte, C.; Anant, P.; Bernal, Y.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A Phase I trial of 19-28z CAR-T cells post-high dose therapy and autologous transplantation (HDT-ASCT) for relapsed and refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C.; Riviere, I.; Senechal, B.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Moskowitz, C.; Giralt, S.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR)
    Meeting Abstract

    Maslak, P. G.; Dao, T.; Bernal, Y.; Chanel, S. M.; Zhang, R.; Frattini, M. G.; Rosenblat, T. L.; Jurcic, J. G.; Rampal, R.; Park, J. H.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19 targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Purdon, T.; Halton, E.; Wang, Y.; Curran, K. J.; Sauter, C. S.; Sadelain, M.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL
    Meeting Abstract

    Park, J.; Riviere, I.; Wang, X.; Bernal, Y.; Purdon, T.; Halton, E.; Curran, K.; Sauter, C.; Sadelain, M.; Brentjens, R.
    Haematologica (2015)

    Fulltext@MSK | Save
  • Phase I clinical trial of autologous CD19-targeted 19-28z CAR T cells in adult patients with Relapsed or refractory B-ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Halton, E.; Quintanilla, H.; Curran, K.; Sauter, C.; Sadelain, M.; Brentjens, R. J.
    Molecular Therapy (2015)

    Fulltext@MSK | Save
  • Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C. S.; Riviere, I.; Bernal, Y.; Wang, X. Y.; Purdon, T.; Yoo, S.; Moskowitz, C. H.; Giralt, S.; Matasar, M. J.; Curran, K. J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save